Showing results (721-730 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research TrialsThumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
The Lancet. HIV|January 9, 2017
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trialJemma O'Connor, Michael J Vjecha, Andrew N Phillips, et al.
The Lancet. HIV|November 20, 2016
Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysisOlalekan A Uthman, Jean B Nachega, Jean Anderson, et al.
The Lancet. HIV|November 22, 2016
Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir StudyMichael Martin, Suphak Vanichseni, Pravan Suntharasamai, et al.
The Lancet. HIV|November 6, 2018
Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort studyJoakim Esbjörnsson, Fredrik Månsson, Anders Kvist, et al.
The Lancet. HIV|February 22, 2017
Effect of availability of HIV self-testing on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trialMuhammad S Jamil, Garrett Prestage, Christopher K Fairley, et al.
The Lancet. HIV|April 4, 2017
Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling studyBohdan Nosyk, Xiao Zang, Jeong E Min, et al.
The Lancet. HIV|March 4, 2019
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort studyRaúl U Hernández-Ramírez, Li Qin, Haiqun Lin, et al.
The Lancet. HIV|July 16, 2019
Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling studyLinwei Wang, Emanuel Krebs, Jeong E Min, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Pageof 79